PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

详细信息    查看全文

• 作者：Patricia Izetti (1) (13) (2) (3)
  Agnes Hautefeuille (4)
  Ana Lucia Abujamra (3) (5) (6)
  Caroline Brunetto de Farias (3) (5) (6)
  Juliana Giacomazzi (1)
  B谩rbara Alemar (1) (2)
  Guido Lenz (7)
  Rafael Roesler (3) (6) (8)
  Gilberto Schwartsmann (3) (6) (9)
  Alessandro Bersch Osvaldt (10)
  Pierre Hainaut (11)
  Patricia Ashton-Prolla (1) (12) (2)
  
• 关键词：Pancreatic cancer ; p53 ; PRIMA ; 1 ; Apoptosis
• 刊名：Investigational New Drugs
• 出版年：2014
• 出版时间：October 2014
• 年：2014
• 卷：32
• 期：5
• 页码：783-794
• 全文大小：4,071 KB
• 参考文献：1. Hoos WA, James PM, Rahib L, Talley A, Fleshman JM, Matrisian LM (2013) Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol 31(27):3432鈥?438 CrossRef
  2. Sarkar FH, Banerjee S, Li Y (2007) Pancreatic cancer: pathogenesis, prevention and treatment. Toxicol Appl Pharmacol 224(3):326鈥?36 CrossRef
  3. Simeone DM (2008) Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 14:5646鈥?648 CrossRef
  4. Conroy T, Desseigne F, Ychou M, Bouch茅 O, Guimbaud R, B茅couarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardi猫re C, Bennouna J, Bachet JB, Khemissa-Akouz F, P茅r茅-Verg茅 D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817鈥?925 CrossRef
  5. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3:157鈥?88 CrossRef
  6. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S et al (2011) Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 10(1):3鈥? CrossRef
  7. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54(11):3025鈥?033
  8. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731鈥?734
  9. Hermanova M, Trna J, Nenutil R, Dite P, Kala Z (2008) Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur J Gastroenterol Hepatol 20:732鈥?39 CrossRef
  10. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR, Sansom OJ (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107(1):246鈥?51 CrossRef
  11. Liang Y, Besch-Williford C, Benakanakere I, Hyder SM (2007) Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Int J Oncol 31:777鈥?84
  12. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282鈥?88 CrossRef
  13. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Paul C, Merup M (2004) Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 127(3):285鈥?91 CrossRef
  14. Russo D, Ottaggio L, Penna I, Foggetti G, Fronza G, Inga A, Menichini P (2010) PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Biochem Biophys Res Commun 402(2):345鈥?50 CrossRef
  15. Roh JL, Kang SK, Minn IL, Califano JA, Sidransky D et al (2011) p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 47(1):8鈥?5 CrossRef
  16. Bao W, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, Issaeva N, Selivanova G, Str枚mblad S (2011) PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo. Cell Cycle 10(2):301鈥?07 CrossRef
  17. Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, Gian矛 F, Vigneri R, Frasca F (2012) Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells. Int J Cancer 130(10):2259鈥?270 CrossRef
  18. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG (2005) PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24(21):3484鈥?491 CrossRef
  19. Russo D, Ottaggio L, Foggetti G, Masini M, Masiello P, Fronza G, Menichini P (2013) PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. Biochim Biophys Acta S0167鈥?889(13):00121鈥?0123
  20. Chou TC, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86:1517鈥?524 CrossRef
  21. Mercalli A, Sordi V, Formicola R, Dandrea M, Beghelli S, Scarpa A et al (2007) A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer 96:1358鈥?367
  22. Lambert JM, Gorzov P, Veprintsev DB, S枚derqvist M, Segerb盲ck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15(5):376鈥?88 CrossRef
  23. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646鈥?74 CrossRef
  24. Wang Z, Sun Y (2010) Targeting p53 for novel anticancer therapy. Transl Oncol 3(1):1鈥?2 CrossRef
  25. Saha MN, Qiu L, Chang H (2013) Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 6:23 CrossRef
  26. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286(5449):2507鈥?510 CrossRef
  27. Maecker HL, Koumenis C, Giaccia AJ (2000) p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res 60(16):4638鈥?644
  28. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS (2008) TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 7(12):2034鈥?038 CrossRef
  29. Chipuk JE, Maurer U, Green DR, Schuler M (2003) Pharmacologic activation of p53 elicits Bax dependent apoptosis in the absence of transcription. Cancer Cell 4(5):371鈥?81 CrossRef
  30. Zhang Y, Fujita N, Tsuruo T (1999) Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 18(5):1131鈥?138 CrossRef
  31. Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1:639鈥?49
  32. Kaneuchi M, Yamashita T, Shindoh M, Segawa K, Takahashi S, Furuta I, Fujimoto S, Fujinaga K (1999) Induction of apoptosis by the p53鈥?73L (Arg鈫扡eu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax. Mol Carcinog 26:44鈥?2 CrossRef
  33. Okaichi K, Wang LH, Sasaki J, Saya H, Tada M, Okumura Y (1999) A point mutation of human p53, which was not detected as a mutation by a yeast functional assay, led to apoptosis but not p21Waf1/Cip1/Sdi1 expression in response to ionizing radiation in a human osteosarcoma cell line, Saos-2. Int J Radiat Oncol Biol Phys 45:975鈥?80 CrossRef
  34. Li J, Lee B, Lee AS (2006) Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 281:7260鈥?270 CrossRef
  35. Kobayashi N, Abedini M, Sakuragi N, Tsang BK (2013) PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation. J Ovarian Res 6(1):7 CrossRef
  36. Gobert C, Andrzej S, Larsen AK (1999) The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. PNAS 96(18):10355鈥?03600 CrossRef
  37. Wiman KG (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29(30):4245鈥?252 CrossRef
  38. Lehmann S, Bykov VJ, Ali D, Andr茅n O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633鈥?639 CrossRef
  
• 作者单位：Patricia Izetti (1) (13) (2) (3)
  Agnes Hautefeuille (4)
  Ana Lucia Abujamra (3) (5) (6)
  Caroline Brunetto de Farias (3) (5) (6)
  Juliana Giacomazzi (1)
  B谩rbara Alemar (1) (2)
  Guido Lenz (7)
  Rafael Roesler (3) (6) (8)
  Gilberto Schwartsmann (3) (6) (9)
  Alessandro Bersch Osvaldt (10)
  Pierre Hainaut (11)
  Patricia Ashton-Prolla (1) (12) (2)
  
  1. Laborat贸rio de Medicina Gen么mica, Centro de Pesquisa Experimental, Hospital de Cl铆nicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, Brazil, 90035-003
  13. Laborat贸rio de Medicina Gen么mica, Hospital de Cl铆nicas de Porto Alegre, Rua Ramiro Barcelos, 2350, 90035-903, Porto Alegre, RS, Brazil
  2. Programa de P贸s-Gradua莽茫o em Gen茅tica e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Av. Bento Gon莽alves, 9500鈥揚r茅dio 43323M, Porto Alegre, RS, Brazil, 91501-970
  3. Laborat贸rio de Pesquisas em C芒ncer, Centro de Pesquisa Experimental, Hospital de Cl铆nicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, Brazil, 90035-003
  4. International Agency for Research on Cancer, 150 Cours Albert Thomas, Lyon, France, 69372
  5. Instituto do C芒ncer Infantil do Rio Grande do Sul, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, Brazil, 90035-003
  6. Instituto Nacional de Ci锚ncia e Tecnologia Translacional em Medicina, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, Brazil, 90035-003
  7. Laborat贸rio de Sinaliza莽茫o e Plasticidade Celular, Universidade Federal do Rio Grande do Sul, Av. Bento Gon莽alves, 9500鈥揚r茅dio 43431, Porto Alegre, RS, Brazil, 91501-970
  8. Laborat贸rio de Neurofarmacologia e Biologia de Tumores Neurais, Departamento de Farmacologia, Instituto de Ci锚ncias B谩sicas da Sa煤de, Universidade Federal do Rio Grande do Sul, Rua Sarmento Leite, 500鈥揝ala 211, Porto Alegre, RS, Brazil, 91501-970
  9. Servi莽o de Oncologia Cl铆nica, Hospital de Cl铆nicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, Brazil, 90035-003
  10. Servi莽o de Cirurgia do Aparelho Digestivo, Hospital de Cl铆nicas de Porto Alegre, Rua Ramiro Barcelos, 2350, Porto Alegre, RS, Brazil, 90035-003
  11. International Prevention Research Institute, 95 Cours Lafayette, Lyon, France, 69006
  12. Departamento de Gen茅tica, Universidade Federal do Rio Grande do Sul, Av. Bento Gon莽alves, 9500鈥揚r茅dio 43323M, Porto Alegre, RS, Brazil, 91501-970
  
• ISSN：1573-0646

文摘